Department of Neurology, University of Chicago, Chicago, IL 60637, USA.
J Clin Neurosci. 2012 Sep;19(9):1310-1. doi: 10.1016/j.jocn.2011.11.027. Epub 2012 Jun 19.
We present a patient with a glioblastoma multiforme treated with bevacizumab who suffered a traumatic subarachnoid hemorrhage (SAH). Trascranial doppler revealed no evidence of vasoconstriction, which has been previously described in a bevacizumab-treated patient. Bevacizumab was resumed five weeks after the SAH without recurrence of bleeding or vasoconstriction. To our knowledge this is the first report of resumption of bevacizumab after SAH.
我们报告了一例接受贝伐单抗治疗的多形性胶质母细胞瘤患者发生创伤性蛛网膜下腔出血（SAH）。经颅多普勒检查未发现血管收缩的证据，此前曾有报道称贝伐单抗治疗的患者存在血管收缩。SAH 后五周恢复使用贝伐单抗，未再出现出血或血管收缩。据我们所知，这是首例报告贝伐单抗治疗后发生 SAH 并恢复使用的病例。
